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Abstract
Background: Septic shock is a prevalent condition that, when not lethal, often causes disturbances
in cognition, mood, and behavior, particularly due to central actions of the inflammatory cytokine
interleukin-6 (IL-6). To identify potential targets to control brain IL-6, we tested if IL-6 produced
by glia is regulated by signal transducer and activator of transcription-3 (STAT3) and glycogen
synthase kinase-3 (GSK3).
Methods: Lipopolysaccharide (LPS) was used to induce inflammatory responses in mice or
cultured primary glia. IL-6 was measured by ELISA and other inflammatory molecules were
measured using an array.
Results: Mouse brain IL-6 levels increased after central, as well as peripheral, LPS administration,
consistent with glia producing a portion of brain IL-6. STAT3 in the brain was activated after
peripheral or central LPS administration, and in LPS-stimulated cultured primary glia. Inhibition of
STAT3 expression, function, or activation reduced by ~80% IL-6 production by primary glia,
demonstrating the dependence on active STAT3. GSK3 promotes STAT3 activation, and array
analysis of inflammatory molecules produced by LPS-stimulated primary glia demonstrated that IL-
6 was the cytokine most diminished (>90%) by GSK3 inhibition. Inhibition of GSK3, and knockdown
of GSK3β, not GSK3α, greatly inhibited IL-6 production by LPS-stimulated primary glia.
Conversely, expression of active STAT3 and active GSK3 promoted IL-6 production. In vivo
inhibition of GSK3 reduced serum and brain IL-6 levels, brain STAT3 activation, and GFAP
upregulation following LPS administration.
Conclusion: STAT3 and GSK3 cooperatively promote neuroinflammation, providing novel targets
for anti-inflammatory intervention.
Background
The inflammatory system is hyperactivated during sepsis,
a potentially lethal condition induced by bacterial infec-
tion that affects nearly 1 million people in the United
States every year [1]. Inflammation is controlled by a bal-
ance of activating and inhibitory signals delivered intrac-
ellularly by transmembrane receptors that recognize
components of invasive bacteria [2]. Sepsis ensues due to
hyperactivation of the innate immune system that causes
a massive production of proinflammatory cytokines and
chemokines that cause vascular leakage and septic shock,
impairing the function of vital organs [1]. Encephalopa-
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failure of other organs such as kidney, liver and lung. Sur-
viving individuals often suffer deleterious consequences
of sepsis, such as cognitive deficits and other signs of long-
term impairments in the central nervous system (CNS)
[3,4].
Interleukin-6 (IL-6) is considered one of the major mark-
ers of lethal sepsis [5], for example as demonstrated in
studies using IL-6 knockout mice [6] but is not a target for
treatment because in short-term mortality studies anti-IL-
6 strategies were unsuccessful [7]. However, increased
brain IL-6 has been associated with severe cognitive
impairments [8-10] and likely contributes to the cognitive
and neuroanatomical long-term consequences of sepsis,
such as persistent behavioral deficits and neuronal loss
[11]. These findings indicate that strategies to reduce IL-6
production may be particularly valuable for protecting the
CNS from damage caused by sepsis.
Recently, glycogen synthase kinase-3 (GSK3) was identi-
fied as a crucial regulator of innate inflammatory proc-
esses [12,13]. GSK3 is a constitutively active Ser/Thr
kinase consisting of two isoforms, GSK3α and GSK3β.
GSK3 was found to strongly promote Toll-like receptor
(TLR)-induced production of several pro-inflammatory
cytokines in monocytes, and GSK3 inhibition rescued 60–
70% of mice from an otherwise lethal septic shock [12].
Subsequently, inhibition of GSK3 was shown to protect
rodents from several peripheral inflammatory conditions
(reviewed in [14]). Members of the signal transducer and
activator of transcription (STAT) family of transcription
factors have central roles in inflammatory reactions, and
STAT3 was considered anti-inflammatory [15], mediating
SOCS-3 or IL-10 signals, and endothelial STAT3 contrib-
utes to anti-inflammatory responses to LPS [16].
Although STAT3 is activated in numerous neuropatholog-
ical conditions such as autoimmune encephalomyelitis
[17] and ischemia [18] and has been implicated in reac-
tive astrogliosis [19], the inflammatory role of STAT3 in
the brain is poorly understood. We report here that in
contrast to its systemic role, STAT3 has proinflammatory
properties in the context of septic shock-induced neuroin-
flammation. This occurs in cooperation with proinflam-
matory GSK3, which is known to participate to the
activation of STAT3 [20], as inhibition of STAT3 or GSK3
greatly reduced IL-6 production by stimulated glia. These
results identify STAT3 and GSK3 as potential targets to
control brain IL-6 production and neuroinflammation.
Methods
Materials
Protein-free E. coli (K235) LPS was prepared as described
[12]. Sources of substances used and solvents were as fol-
lows: IFNγ (R&D Systems), SB216763 (in DMSO; Tocris),
kenpaullone, indirubin-3'-monoxime, BIO (6-bromoin-
dirubin-3'-oxime), GSK3 inhibitor II, AG490 (each in
DMSO; Calbiochem), LiCl (in water; Sigma), and JSI-124
(cucurbitacin, in DMSO; National Cancer Institute Devel-
opmental Therapeutic Program). Mouse IL-1β, TNFα, IL-
6, IL-10 and IFNγ were measured with ELISA kits accord-
ing to the manufacturer's instructions (eBioscience). The
concentrations of 62 inflammatory proteins (listed in
Additional files 1 and 2) were measured with inflamma-
tory molecule antibody arrays according to the manufac-
turer's instructions (Raybiotech).
Mice
Male C57Bl/6 mice (8–10 weeks) were housed in a light
and temperature controlled room, Mice were injected
intraperitoneally (ip) with E. coli K235 LPS (10 μg/g in
200 μL saline) followed by measurements of cytokines by
ELISA in the serum and brain regions. In some mice, lith-
ium was administered in pelleted food containing 0.2%
lithium carbonate (Harlan-Teklad) for 3 weeks before LPS
treatment, which resulted in serum lithium concentra-
tions of 0.53 ± 0.03 mM (n = 4). For central administra-
tion using ketamine/xylazine (100 mg/kg, 10 mg/kg)
anesthesia, LPS (10 μg/1 μL) was slowly infused stereotax-
ically into each lateral ventricle (icv; relative to bregma 0.4
mm posterior, ± 1 mm lateral, 2.2 mm depth), mice were
sacrificed 2, 4, or 8 hr after treatment, and tissue from the
hippocampus adjacent to the ventricle (ventricular infu-
sion zone) and from the distant occipital cortex was ana-
lyzed for cytokines by ELISA. For immunoblotting, brain
regions were homogenized in ice-cold lysis buffer con-
taining 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM
EDTA, 1% Triton X-100, 10% glycerol, 1 μg/mL of leupep-
tin, aprotinin, and pepstatinA, 1 mM orthovanadate, 50
mM NaF, 0.1 μM okadaic acid, 1 mM PMSF. The lysates
were centrifuged at 14 000 rpm for 10 min to remove
insoluble debris. Protein concentrations in the superna-
tants were determined in duplicate using the Bradford
protein assay. Mice were housed and treated in accord-
ance with National Institutes of Health and the University
of Alabama at Birmingham Institutional Animal Care and
Use Committee guidelines.
Cell culture, immunoblotting, and cell viability assay
For murine primary neurons, the hippocampus from 1
day old C57Bl/6 mice was isolated and incubated in 0.1%
trypsin (Invitrogen) and the cells mechanically dissoci-
ated using a fire-polished pipette. Cells were plated in
DMEM/F12 medium supplemented with 10% FBS, 0.3%
glucose, 2 mM glutamine, 10 U/mL penicillin and 10 μg/
mL streptomycin in poly-D-lysine-coated six-well plates.
Twelve hours after plating, the medium was replaced with
Neurobasal medium supplemented with B27 and 0.5 mM
glutamine (Invitrogen) to promote neuronal survival and
to inhibit the growth of non-neuronal cells. Neurons werePage 2 of 11
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glia were prepared from the cerebral cortex of 1 day old
C57Bl/6 mice as described [21], cultured in DMEM/F12
medium supplemented with 10% FBS, 0.3% glucose, 2
mM L-glutamine, 10 U/mL penicillin and 10 μg/mL strep-
tomycin. For separation of astrocytes and microglia, after
10 days of culture the cells were shaken (30 hr; 250 rpm),
resulting in >99% pure astrocytes as determined by
immunostaining with the astrocyte marker glial fibrillary
acidic protein (GFAP). After the first hour of shaking, the
medium containing microglia cells was collected and
microglia were cultured in the same medium as astrocytes.
For expression experiments, cells were rinsed twice with
DMEM/F12 medium without supplements, infected with
50 moi of the designated adenovirus for 30 min, supple-
mented medium was added for incubation for 36–48 h,
and infected cultures were examined for adequate infec-
tion efficiency (80%) as assessed by GFP fluorescence
after infection with GFP adenovirus. For knockdown
experiments, cells were transfected using liposome-medi-
ated transfection reagent LipofectAMINE RNAiMAX (Inv-
itrogen) with 50 nM siRNA according to the
manufacturer's instructions with STAT3 prevalidated
siRNA [22], silencer negative control (Ambion), or GSK3α
and GSK3β siRNA (Smart pool; Dharmacon). For experi-
mental treatments, cells were pretreated with the indi-
cated inhibitors for 30 min followed by treatment with
100 ng/mL LPS, 1 ng/mL IFNγ, or both, for the indicated
times. Following treatments, cells were washed twice with
phosphate-buffered saline (PBS) and were lysed with lysis
buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM
EDTA, 1% Triton X-100, 10% glycerol, 1 μg/mL of leupep-
tin, aprotinin, and pepstatinA, 1 mM orthovanadate, 50
mM NaF, 0.1 μM okadaic acid, 1 mM phenylmethanesul-
fonyl fluoride). The lysates were centrifuged at 14 000
rpm for 10 min. Protein concentrations were determined
in duplicate using the Bradford protein assay. Immunob-
lotting was carried out as described before [20] using anti-
bodies to phospho-Tyr705-STAT3, total STAT3 (Cell
Signaling Technology), GFAP, GSK3α/β (Millipore), and
β-actin (Sigma). Immunoblots were developed using
horseradish peroxidase-conjugated goat anti-mouse, or
goat anti-rabbit IgG, followed by detection with enhanced
chemiluminescence, and the protein bands were quanti-
tated with a densitometer. Cell viability was assessed by a
colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay. A multi-well scan-
ner was used to measure the absorbance at 570–630 nm
dual wavelengths. Statistical significance between groups
was evaluated by Student's t-test.
Results
IL-6 robustly accumulates in the brain after sepsis
IL-6 in the cerebral cortex, cerebellum, and hippocampus
was markedly increased 4 hr after peripheral LPS adminis-
tration, which reflected the increased serum IL-6 level,
whereas LPS administration slightly increased cortical and
serum levels of TNFα, but not of IL-1β, at this time (Figure
1A–C). IL-6 present in brain regions was likely partly pro-
Levels of cytokines in plasma and the brain parenchyma in r sponse to sepsisFigure 1
Levels of cytokines in plasma and the brain paren-
chyma in response to sepsis. Serum and brain region lev-
els of A, IL-6, B, TNFα, and C, IL-1β were measured 4 h after 
ip injection of 10 μg/g LPS or saline to evaluate the early out-
comes of acute sepsis. Means ± SEM; n = 3;* p < 0.05.Page 3 of 11
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IL-6 accumulated both in the ventricular infusion zone
and in the distant occipital cortex, indicating centrally-
induced spreading inflammation (Figure 2A). Central LPS
infusion also moderately increased brain levels of TNFα
and IFNγ in both brain regions but with a persistence in
the ventricular infusion zone, while IL-1β and the anti-
inflammatory cytokine IL-10 levels slightly increased at
late time points in the ventricular infusion zone only (Fig-
ure 2B–E). Administration of saline vehicle had more
modest effects than LPS on the levels of cytokines in the
brain. Thus, in response to sepsis, IL-6 robustly accumu-
lates in the brain and is at least partly produced by the cen-
tral inflammatory system, although some contribution
from the periphery cannot be ruled out.
IL-6 and other cytokines, such as interferons, induce the
activation of STAT3 by receptor-induced Janus kinase
Brain cytokines and STAT3 activationFigure 2
Brain cytokines and STAT3 activation. A, IL-6, B, TNFα, C, IL-1β, D, IFNγ, and E, IL-10, were measured in homogenates 
(100 μg) of the ventricular infusion zone (V) or the distant occipital cortex (O), 2, 4 or 8 h after LPS (10 μg/1 μL; icv) or 4 h 
after saline (icv) injection. Control mice were not subjected to surgery. Means ± SEM.; n = 4–5 mice/group, *p < 0.05 4 hr 
treatments compared to mice injected with saline. Activation of STAT3 was measured by immunoblotting phospho-Tyr705-
STAT3 and total STAT3, F, in cerebral cortex 4 h after ip injection of LPS or, G, in the ventricular infusion zone (V) or occipital 
cortex (O) 2, 4 or 8 h after icv infusion of LPS or 4 h after saline and compared to mice subjected to anesthesia only. STAT3 
immunoblotted from cultured astrocytes is shown as a positive control.Page 4 of 11
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Phospho-Tyr705-STAT3 in the brain was increased 4 hr
after either ip (Figure 2F) or icv LPS administration (Fig-
ure 2G), confirming that STAT3 is activated in the brain
after sepsis [24,25]. Examined 6 hr after treatment with
LPS (100 ng/mL), STAT3 was activated in primary astro-
cytes and microglia (Figure 3A). Treatment with LPS alone
did not stimulate STAT3 in primary neurons, but neuro-
nal STAT3 was activated after treatment with conditioned
medium from treated astrocytes, indicating that a factor
released from glia, such as IL-6, can stimulate neuronal
STAT3. Thus, STAT3 can be activated in all three types of
cells during in vivo inflammation.
The production of IL-6 was also evaluated in primary glia
after stimulation with LPS or with IFNγ co-administration
with LPS, which amplifies LPS-induced cytokine produc-
tion. There was a time-dependent increase in IL-6 produc-
tion in response to LPS (100 ng/mL) that was amplified
by co-stimulation with 1 ng/mL IFNγ (Figure 3B). Inflam-
matory molecule array analysis showed a large increase in
the production of IL-6 by primary glia in response to stim-
ulation with LPS plus IFNγ (Figure 3C). Several other
products implicated in the pathogenesis of sepsis were
also induced by this treatment, including IL-12p40,
CCL5/RANTES, CXCL1/KC, CCL9/MIP-1γ, CXCL2/MIP-
2, P-Selectin, TIMP-1 and CCL2/MCP-1 (Figure 3C).
STAT3 participates in IL-6 production
To examine the mechanisms regulating the production of
IL-6, we tested if STAT3 not only was activated by IL-6 but
also participated in a feed-forward loop promoting IL-6
production in primary glia as was recently identified in B
lymphocytes [26]. IL-6 production in glia induced by
treatment with LPS plus IFNγ was greatly reduced by
downregulation of STAT3 expression by siRNA (Figure
4A), by pharmacological inhibition with the STAT3-spe-
cific inhibitor JSI-124 (cucurbitacin) [27] (Figure 4B), or
with the JAK2 inhibitor AG490 (Figure 4C), neither of
which impaired cell viability (Figure 4D). These findings
indicate that STAT3 may not only propagate the IL-6 sig-
nal after sepsis but also contributes to inflammation-
induced IL-6 production in glia.
IL-6 production is strongly dependent on GSK3
Since STAT3 activation requires active GSK3 [20], systemic
IL-6 production is controlled by GSK3 [12], and GSK3 is
abundantly expressed in the brain, we tested if GSK3 con-
trols IL-6 production by astrocytes and microglia, first
with the selective inhibitor lithium [28] using a cytokine
array. Among the 12 molecules detected to be induced by
treatment with LPS plus IFNγ in glia, the production of
TIMP-1 and VCAM-1 were independent of GSK3, whereas
active GSK3 decreased the expression of CXCL2/MIP-2
and increased the expression of CXCL1/KC, IL-12p40,
CCL9/MIP-1γ, CCL2/MCP-1, P-Selectin and CCL5/
RANTES (Figure 3C and 5A). However, most promi-
nently, active GSK3 promoted IL-6 production by 16-fold,
showing that IL-6 production by glia is strongly depend-
ent on GSK3. Confirmation by ELISA showed that inhibi-
tion of GSK3 with lithium treatment reduced the time-
dependent production of IL-6 induced by LPS and its
potentiation by IFNγ in primary astrocytes (Figure 5B).
The dependency of IL-6 production in primary astrocytes
on GSK3 was confirmed by the strong inhibition exerted
by four other structurally diverse GSK3 inhibitors on IL-6
produced in response to LPS or to a combination of LPS
plus IFNγ (Figure 5C), which was not due to changes in
cell viability (Figure 5D). Inhibition of GSK3 also strongly
reduced IL-6 production in primary microglia (Figure 5E).
siRNA-mediated knockdown by 75% of GSK3β, but not
of GSK3α, greatly reduced the production of IL-6 by pri-
mary enriched astrocytes induced by LPS and its potentia-
tion by IFNγ (Figure 5F), indicating that GSK3β
predominantly regulates IL-6 production.
GSK3 and STAT3 are sufficient to stimulate IL-6 
production in glia
Since both active STAT3 and active GSK3 were necessary
for IL-6 production, the expression of active forms of each
was introduced using adenoviruses in primary enriched
astrocytes to examine their effects on IL-6 production.
These included STAT3C, in which covalent bonds
between cysteines establishes the active dimer conforma-
tion [29], and constitutively active S9A-GSK3β and S21A-
GSK3α, where serines subject to inhibitory phosphoryla-
tion were mutated to alanines to prohibit inhibitory ser-
ine phosphorylation. Expression of active S21A-GSK3α
and S9A-GSK3β together increased IL-6 production and
this was increased a further 4.5-fold with co-expression of
STAT3C (Figure 5G). This demonstrates that GSK3 and
STAT3 were both necessary, and together sufficient, to
stimulate IL-6 production in glia cells.
GSK3 inhibition reduces IL-6 signaling in the brain
The capacity of GSK3 inhibitors to dampen IL-6 produc-
tion in glia raised the possibility that GSK3 inhibitors may
be beneficial for reducing neuroinflammation. To test this
hypothesis, mice were treated with lithium because it is
the only GSK3 inhibitor that is well-established to be
effective in the CNS after peripheral administration [26].
In mice treated with lithium, the serum IL-6 level 18 hr
after LPS administration was 67% lower than in mice not
given lithium (Figure 6A). This matches a previous report
that the GSK3 inhibitor SB216763 greatly reduced serum
IL-6 after LPS challenge [12]. IL-6 levels were elevated in
the cerebral cortex and cerebellum (Figure 6A), but not
hippocampus (not shown) 18 hr after LPS administra-
tion, and lithium pretreatment reduced these increases in
IL-6. In mice pretreated with lithium, there was also a sig-Page 5 of 11
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STAT3 activation and cytokine production in cultured cellsFigure 3
STAT3 activation and cytokine production in cultured cells. A, Phospho-Tyr705-STAT3 and total STAT3 were immu-
noblotted after treatment with LPS (100 ng/mL) for 6 h of primary cultures of astrocytes, microglia, or neurons. Some of the 
neuronal cultures also were treated for 6 h with conditioned media (CM) from LPS-treated (6 h) astrocytes. B, Primary 
enriched astrocytes were treated with vehicle (0), or with 100 ng/mL LPS, 1 ng/mL IFNγ, or both, for 2, 4, 6, or 8 h, followed 
by measurements of IL-6. Means ± SEM; n = 5; *p < 0.05 compared to LPS alone. C, Primary enriched astrocytes were stimu-
lated with LPS (100 ng/mL) and IFNγ (1 ng/mL), with or without the selective GSK3 inhibitor lithium (LiCl, 20 mM), for 6 h. 
Culture supernatants were incubated with an array membrane that detects 62 proteins in duplicate. Boxes indicate the loca-
tion of the detected 13 proteins induced by LPS plus IFNγ. Positive controls are in the upper left and lower right corners (high 
intensity spots) and negative controls in the upper right corner (no spots).
Journal of Neuroinflammation 2009, 6:9 http://www.jneuroinflammation.com/content/6/1/9nificant reduction in the activating tyrosine-phosphoryla-
tion of STAT3 following LPS administration in the
cerebral cortex, hippocampus, and cerebellum (Figure
6B). Furthermore, inhibition of GSK3 with lithium also
reduced the activation of astrocytes, as measured by the
astrocyte marker GFAP immunoreactivity, following LPS
treatment (Figure 6C). Since STAT3 promotes GFAP
expression [30], this indicates that lithium's inhibition of
IL-6 production and STAT3 activation reduces expression
of STAT3-dependent astrocyte-specific genes such as
GFAP, resulting in reduction of astrogliosis induced by
LPS.
Discussion
The inflammatory response mounted in the brain in
response to many types of insults is crucial to control and
counteract detrimental effects of the insults on neurons.
However, neuroinflammation that is severe or chronic can
itself damage neurons due to excessive production of
cytokines and other inflammatory molecules by astrocytes
and microglia [31,32]. Therefore, identification of mech-
anisms capable of controlling neuroinflammation pro-
vide avenues to interrupt the inflammatory process to
prevent its deleterious consequences. Here, we identify
novel cooperative actions of STAT3 and GSK3 that control
IL-6 production by glia during sepsis-induced neuroin-
flammation. The production of IL-6 by glia was largely
blocked by interventions inhibiting the activity of STAT3
or GSK3β, revealing the strong dependence of IL-6 pro-
duction in glia on these signaling molecules.
Sepsis caused a large increase in IL-6 in the serum, some
of which likely accounted for the increased brain levels of
IL-6. However, IL-6 also is produced locally in the brain
since its level increased after centrally administered LPS
and it was produced by LPS-stimulated primary astrocytes
and microglia in culture. IL-6 in the brain is apparently a
dual-edged sword, having both beneficial effects but also
deleterious effects [33], likely depending on the magni-
tude and duration of its stimulated production. IL-6 may
have acute neuroprotective and regenerative effects on
neurons [34], which have been reported to depend on its
ability to inhibit the synthesis of TNF, induce nerve
growth factor, and promote neuronal differentiation and
survival [35]. However, chronic or high increases in IL-6
levels in the brain lead to neuronal and cognitive impair-
ments [8-11]. The actions of IL-6 are partly mediated by its
effects on glia, but it also is not clear if the effects of IL-6
on astrocytes and microglia are beneficial or detrimental.
IL-6 is considered an important inducer of astrogliosis,
promoting reactive responses regulating the activation
state of astrocytes [36,37], but chronic or excessive activa-
tion of glia is often associated with neuronal loss and may
contribute to many widespread neurodegenerative dis-
eases, such as Alzheimer's disease and multiple sclerosis
[38].
Our findings indicate that inhibition of STAT3 and GSK3
provide mechanisms to intervene to reduce IL-6 produc-
tion. In glia, IL-6 production was highly dependent on the
transcription factor STAT3, suggesting that by activating
STAT3 IL-6 promoted its own production, as well as acti-
vating astrocytes as indicated by increases in the astrocyte
STAT3 contributes to the LPS-induced IL-6 production in primary enriched astrocytesFigure 4
STAT3 contributes to the LPS-induced IL-6 production in primary enriched astrocytes. Primary enriched astro-
cytes were treated with 100 ng/mL LPS, 1 ng/mL IFNγ, or both, for 6 h, followed by measurements of IL-6. A, Inhibition of IL-6 
production after 36 h siRNA-mediated knockdown of STAT3. The knockdown efficiency was ensured by immunoblotting for 
STAT3 (inset). (n = 6,*p < 0.05 compared to LPS plus IFNγ with control siRNA SNC). B, Inhibition of LPS plus IFNγ (6 h) stim-
ulated IL-6 production by inhibition of STAT3 with 10 μM JSI-124 (n = 8, *p < 0.05 compared to LPS plus IFNγ with DMSO). C, 
Inhibition of LPS plus IFNγ (6 h) stimulated IL-6 production by treatment with 30 (middle bars, light shade) or 100 μM AG490 
(right bars, medium shading) (n = 5, *p < 0.05 compared to LPS plus IFNγ with DMSO). Means ± SEM. D, Cell viability: Primary 
enriched astrocytes were treated with vehicle DMSO (left, white bars), 100 ng/mL LPS, 1 ng/mL IFNγ, or both, and with 10 μM 
JSI-124 or 100 μM AG490 for 6 h and viability was assessed by a MTT assay. Means ± SEM; n = 3.Page 7 of 11
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GSK3 promotes IL-6 productionFigure 5
GSK3 promotes IL-6 production. A, Quantitation of the effects of lithium treatment on inflammatory molecules produced 
by primary enriched astrocytes stimulated with LPS (100 ng/mL) and IFNγ (1 ng/mL) for 6 h and analyzed by cytokine array, as 
described in Figure 3C. B, Time-dependent production of IL-6 by primary enriched astrocytes treated with vehicle (0), LPS 
(100 ng/mL), IFNγ (1 ng/mL), or both, in the absence and presence of 20 mM lithium. White bars indicate that no GSK3 inhibi-
tor was added. *p < 0.05 compared to LPS plus IFNγ. C, IL-6 production by primary enriched astrocytes (n = 7) treated with 1 
ng/mL IFNγ, 100 ng/mL LPS, or both, without or with 20 mM lithium or 10 μM other GSK3 inhibitors, for 6 h. White bars indi-
cate DMSO vehicle with no GSK3 inhibitor. *p < 0.05 compared to LPS plus IFNγ without any GSK3 inhibitor. D, Cell viability: 
Primary enriched astrocytes were treated with 100 ng/mL LPS, 1 ng/mL IFNγ, or both, and with 20 mM lithium, 10 μM 6-bro-
moindirubin-3'-oxime (BIO), 10 μM kenpaullone, 10 μM GSK3 inhibitor II, or 10 μM SB216763 for 6 h and viability was 
assessed by a MTT assay. White bars indicate DMSO vehicle with no GSK3 inhibitor. Means ± SEM; n = 3. E, IL-6 production 
by primary microglia (n = 4) treated with 1 ng/mL IFNγ, 100 ng/mL LPS, or both, without or with 20 mM lithium or 10 μM 
SB216763, for 6 h. White bars indicate that no GSK3 inhibitor was added. *p < 0.05 compared to LPS plus IFNγ without any 
GSK3 inhibitor. F, IL-6 production by primary enriched astrocytes after 48 h siRNA-mediated knockdown of GSK3α, GSK3β, 
or both, and stimulation with LPS (100 ng/mL), IFNγ (1 ng/mL), or both, for 6 h (n = 5, *p < 0.05 compared to corresponding 
control siRNA SNC values). G, Cooperation between GSK3 and STAT3 to induce IL-6 production by primary enriched astro-
cytes, after 36 h expression of control GFP, S21A-GSK3α, or S9A-GSK3β, with or without expression of STAT3C (n = 3;*p < 
0.05). Means ± SEM.
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GSK3 inhibition attenuates IL-6 production and astrogliosisFigure 6
GSK3 inhibition attenuates IL-6 production and astrogliosis. Mice were fed for 3 weeks without or with lithium chow. 
A, Serum and brain region homogenate (100 μg protein) levels of IL-6 were measured 18 h after ip injection of LPS or saline 
vehicle control (C) to evaluate the relative long-term outcomes of acute sepsis (n = 4–6 mice/group, *p < 0.05, compared to 
mice injected with LPS without lithium). B, Activation of STAT3 was measured by immunoblotting phospho-Tyr705-STAT3 in 
brain regions 18 h after ip injection of LPS. Means ± SEM (n = 4–6 mice/group, *p < 0.05 compared to mice injected with LPS 
without lithium). C, GFAP in brain regions 18 h after LPS (ip). Means ± SEM (n = 4–6 mice/group,*p < 0.05, compared to mice 
injected with LPS without lithium).
Journal of Neuroinflammation 2009, 6:9 http://www.jneuroinflammation.com/content/6/1/9reactive marker GFAP. This amplification loop was
recently identified in B cells, as B cell-lymphoma with
high expression of STAT3 exhibited elevated production
of IL-6 [26]. Our study expands this observation by show-
ing this mechanism of a feed-forward loop is activated in
the brain after sepsis. Thus, this may provide a target to
specifically dampen the effects of IL-6 on glia after sepsis.
GSK3 also was required for IL-6 production, as inhibitors
of GSK3 greatly attenuated IL-6 production. Although
other cytokines and chemokines also were regulated by
GSK3 inhibitors, IL-6 displayed the greatest dependence
on GSK3. These findings likely signify cooperative actions
of STAT3 and GSK3 in promoting IL-6 production since
STAT3 activation is dependent on GSK3 [20]. Thus, GSK3
is capable of promoting IL-6 production by contributing
to the activation of both STAT3 and NF-κB [39].
Conclusion
The identification of GSK3 as a regulator of IL-6 produc-
tion in the brain expands the already well-known role of
GSK3 as an integrator of many signaling pathways
involved in inflammatory signaling [14] and indicates
that inhibition of GSK3 may provide a new therapeutic
strategy to counteract the detrimental consequences of
sepsis in the brain. Furthermore, in contrast to interven-
tions targeting individual transcription factors, inhibiting
GSK3 enables simultaneous regulation of multiple tran-
scription factors involved in inflammatory signaling, a
therapeutic potential strengthened by the rapidly growing
armament of GSK3 inhibitors that includes lithium, a
drug already used therapeutically in human patients.
These agents may contribute to the regulation of inflam-
mation, which continues to be a pressing problem
because of the widespread association of excessive inflam-
mation with many diseases, and particularly neuroinflam-
mation, which contributes to a broad range of
neurodegenerative diseases.
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